PLK1 and cancer: Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) analysis revealed MC hub/prognostic genes show highest sensitivity towards two compounds - BI-2536 (PLK1 inhibitor) and AR-42 (histone deacetylase (HDAC) inhibitor).